Recombinant Human ICOSLG protein, His-Avi-tagged, Biotinylated

• Cat.No.: CD79B-259HB
• Product Overview: Biotinylated Human CD79B Protein is expressed from mammalian with a His tag and Avi tag at the C-terminal. It contains Ala 29 - Asp 159.

Specification

• Description: CD79B (also known as B29, Ig beta and B cell antigen receptor complex-associated protein beta-chain) is a 36-40 kDa member of the Ig-Superfamily. It is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
• Source: HEK293
• Species: Human
• Tag: His&Avi
• Form: Supplied as 0. 22um filtered solution in PBS (pH 7. 4).
• Molecular Mass: The protein has a predicted MW of 18. 1 kDa. Due to glycosylation, the protein migrates to 33- 42KDa based on Bis-Tris PAGE result.
• Protein length: Ala 29 - Asp 159
• Endotoxin: Less than 0. 1EU per ug by the LAL method.
• Purity: > 95% as determined by SDS-PAGE; > 95% as determined by HPLC
• Storage: The product should be stored at -70°C. Please do not repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: CD79B CD79b molecule, immunoglobulin-associated beta [ Homo sapiens ]
• Official Symbol: CD79B
• Synonyms: B29; B29B-cell-specific glycoprotein B29; B-cell antigen receptor complex-associated protein beta chain; CD79B antigen (immunoglobulin-associated beta); CD79b antigen; CD79b molecule, immunoglobulin-associated beta; CD79B; IGB; IGBAGM6; Ig-beta; Immunoglobulin-associated B29 protein
• Gene ID: 974
• mRNA Refseq: NM_000626. 4
• Protein Refseq: NP_000617. 1
• MIM: 147245
• UniProt ID: P40259

Reviews

04/26/2023

Renowned for its reliability and consistency, this protein offers researchers the confidence to achieve accurate and reproducible results in their studies.

11/16/2021

The CD79B protein comes highly recommended for its outstanding performance in ELISA assays.

10/26/2018

One notable advantage of the CD79B protein is the excellent technical support provided by its manufacturer.

Q&As

How does CD79B-targeted immunotherapy differ from traditional chemotherapy in treating B cell malignancies?

CD79B-targeted immunotherapy aims to specifically target B cells, potentially reducing side effects compared to non-specific chemotherapy.

How does CD79B contribute to the development of personalized treatment strategies for B cell diseases?

Analyzing CD79B expression helps tailor treatment plans, allowing for more personalized and effective approaches.

Can CD79B be used as a biomarker for minimal residual disease in B cell malignancies?

Yes, monitoring CD79B levels can aid in detecting minimal residual disease, providing insights into treatment response.

Are there any challenges or limitations associated with relying on CD79B as a diagnostic marker?

Variability in CD79B expression among different B cell disorders may pose challenges in its use as a standalone diagnostic marker.

Are there any clinical trials investigating the therapeutic potential of CD79B-targeted drugs?

Yes, several clinical trials are exploring the efficacy of CD79B-targeted drugs in various B cell disorders.